复宏汉霖PD-1新药“出海”日本 最早将于2028年产生销售提成

Core Viewpoint - Shanghai Junshi Biosciences Co., Ltd. (referred to as "Junshi") and Eisai Co., Ltd. (referred to as "Eisai") have announced an exclusive commercialization and co-development agreement for the PD-1 monoclonal antibody Hansizhuang (also known as "PD-1 new drug") in Japan, marking a significant step in Junshi's international expansion [1] Group 1 - Junshi will receive an upfront payment of $75 million from Eisai, with potential additional payments of up to $80.01 million in regulatory milestone payments and up to $233.3 million in sales milestone payments, totaling a potential value of $388 million (excluding sales royalties) for the Japanese market [1] - The agreement indicates a strong performance for Hansizhuang's entry into the Japanese market, as noted by a securities analyst [1] - Junshi's CEO, Dr. Zhu Jun, emphasized that Hansizhuang has shown good potential across various tumor types, and Japan is a key step in its internationalization process [1] Group 2 - Junshi has strategically planned for the Japanese market for three years and initially intended to independently commercialize Hansizhuang in Japan, but opted for collaboration with Eisai due to their attractive offer [2] - Currently, Hansizhuang is being developed for indications in Japan, including extensive-stage small cell lung cancer and non-microsatellite instability high metastatic colorectal cancer, with plans for a clinical study on perioperative treatment for gastric cancer [2] - The company expects to submit a marketing application for extensive-stage small cell lung cancer in Japan during Eisai's fiscal year 2026, with approvals for both extensive-stage small cell lung cancer and non-microsatellite instability high metastatic colorectal cancer anticipated by 2028, and for gastric cancer by 2029 [2][3] Group 3 - Hansizhuang has already been approved in over 40 countries and regions, including the EU and Southeast Asia, for the treatment of extensive-stage small cell lung cancer [3] - Junshi continues to explore additional indications for Hansizhuang, focusing on high-incidence tumor areas such as lung cancer and gastrointestinal tumors, and aims to investigate its potential in diseases where PD-1 monoclonal antibodies have not yet been applied [3]